Hims & Hers Health Expands Weight Loss Medications with Eli Lilly's Zepbound and Mounjaro
- Hims & Hers Health now offers Eli Lilly’s weight loss medications, Zepbound, Mounjaro, and generic liraglutide, enhancing telehealth services.
- The company plans personalized weight loss programs, projecting $725 million annual revenue from its weight loss product line.
- Hims & Hers is advocating for compounded medications while navigating regulatory challenges to maintain its market position.
### Hims & Hers Health Expands Weight Loss Offerings with Eli Lilly Medications
Hims & Hers Health elevates its position in the telehealth sector by announcing that patients can now access Eli Lilly’s weight loss medications, Zepbound and Mounjaro, along with generic liraglutide, through its platform. This strategic move aligns with the company's recent launch of a weight loss program aimed at addressing the growing demand for effective weight management solutions. In an environment marked by regulatory challenges and supply chain hurdles, the introduction of these medications signifies a critical expansion of Hims & Hers’ offerings in a competitive market. Zepbound and Mounjaro are priced at a premium rate of $1,899 per month, while liraglutide, which requires daily injections, is available for $299 monthly and may offer a less effective option for some patients.
Dr. Craig Primack, senior vice president of weight loss at Hims & Hers, emphasizes the company's commitment to enhancing its weight loss services, indicating plans for a more personalized approach in the future. The company aims to leverage its experience and existing infrastructure to create tailored programs that cater to individual patient needs. With the potential to generate significant revenue—projecting at least $725 million annually from its weight loss products, excluding compounded semaglutide contributions—Hims & Hers is poised to capitalize on the increasing popularity of weight loss medications. In 2024 alone, the company reported over $225 million in revenue from prescribing compounded semaglutide, showcasing the effectiveness of its existing product lines.
Despite the positive reception of the new medications, Hims & Hers faces challenges, particularly with the recent resolution of the semaglutide injection shortage announced by the FDA. This development necessitates a recalibration of the company’s compounded medication offerings. To maintain its market position, Hims & Hers is also advocating for the preservation of compounded medications, encouraging users to engage with Congress and the FDA. The company’s proactive stance signals its intention to navigate the complexities of the regulatory landscape while continuing to meet the needs of its patient base.
In addition to its weight loss initiatives, Hims & Hers Health has experienced a notable increase in share value, rising 27% in 2025 following a remarkable 172% jump the previous year. This growth underscores investor confidence in the company's strategic direction and product offerings. However, recent market dynamics have shown fluctuations, with some analysts expressing concerns over the high price point of Zepbound, which could impact patient accessibility and overall demand.
Hims & Hers continues to position itself as a leader in the telehealth sector, particularly in the increasingly competitive realm of weight management solutions. As the company rolls out its new weight loss medications, it maintains a focus on patient-centered care and innovation to drive future growth.